Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Am J Hematol. 2021 Apr 1;96(4):E111-E114. doi: 10.1002/ajh.26095. Epub 2021 Jan 31.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1 / antagonists & inhibitors
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Erythrocyte Transfusion*
  • Female
  • Fever / chemically induced
  • Follow-Up Studies
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Male
  • Membrane Glycoproteins / antagonists & inhibitors
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / epidemiology
  • Myelodysplastic Syndromes / therapy
  • Neutropenia / chemically induced
  • Pneumonia / chemically induced
  • Proof of Concept Study
  • Risk
  • Thrombocytopenia / chemically induced

Substances

  • Antibodies, Monoclonal
  • Immunologic Factors
  • Membrane Glycoproteins
  • daratumumab
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1